What Clinical Evidence Says About Compounded GLP-1 Safety The active ingredient in compounded semaglutidethe GLP-1 receptor agonist molecule itselfhas the same chemical structure and mechanism of action as brand-name formulations
When Continuation May Be Appropriate In some cases, continuing GLP-1 therapy may still be reasonable
compounding regulations, using the same active pharmaceutical ingredients (semaglutide, tirzepatide) found in FDA-approved branded drugs
[1] Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, and diarrhea, which typically diminish with continued use
A study by Kaufman KR, Struck PJ
While your body naturally produces GLP-1, some people may benefit from medications that mimic its effects. In that case, a prescription is administered